Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common neoplasms and is considered the third leading cause of cancer-related mortality worldwide ([@b1-ol-0-0-11037]). Spontaneous rupture with intratumoral hemorrhage is one of the life-threatening complications of HCC. Although the incidence of HCC rupture is \~3--15%, it is associated with high mortality rates that range between 32 and 75% ([@b2-ol-0-0-11037]--[@b5-ol-0-0-11037]). The disease prognosis remains poor in the absence of appropriate treatment in the acute phase ([@b6-ol-0-0-11037]). Therefore, appropriate treatment selection for patients with HCC rupture is imperative.

The main treatment for HCC rupture includes emergency or staged hepatectomy and transcatheter arterial chemoembolization (TACE) ([@b7-ol-0-0-11037]). Several studies have reported a promising outcome following emergency liver resection ([@b8-ol-0-0-11037]--[@b10-ol-0-0-11037]). However, patients with advanced HCC tend to have poor hepatic function as a result of chronic hepatitis or liver cirrhosis. Severe cirrhosis or poor patient status, as determined by vital signs and blood examination, often reduce the tolerance of patients to surgery. Conventional TACE has been a widely accepted therapeutic option for unresectable HCC and has shown optimal efficacy ([@b11-ol-0-0-11037]). TACE is a treatment modality resulting from ischemic necrosis due to arterial embolization. This condition requires the use of cytotoxic drugs and results in a cytotoxic effect ([@b12-ol-0-0-11037]). In addition to the prevention of tumor progression, TACE is useful in controlling hemorrhage in patients with HCC rupture ([@b13-ol-0-0-11037]). However, severe complications, including hepatic failure, biliary tract injury, hepatic encephalopathy and renal failure, have been reported in previous studies ([@b14-ol-0-0-11037]--[@b16-ol-0-0-11037]). Therefore, assessment of the efficacy and safety of TACE treatment in patients with a ruptured tumor is particularly important. To the best of our knowledge, no definite recommendation has been issued regarding the optimal therapeutic approach in cases of HCC rupture, and the comparative survival benefits of surgery and TACE remain unclear.

In the present retrospective study, the adverse reactions of TACE and the independent predictors of post-treatment survival outcomes in patients with spontaneously ruptured HCC were investigated. The results were compared with the survival outcomes of TACE and surgery in patients at a single center in China.

Materials and methods
=====================

### Patients

The present retrospective study included patients who underwent TACE or surgery for spontaneous HCC rupture between April 2015 and October 2017 at the Department of Hepatic Carcinoma of Fudan University Affiliated Zhongshan Hospital (Shanghai, China). A total of 70 cases with HCC were enrolled. No patient had a recent history of HCC treatment, such as surgery or TACE, within 1 month prior to the diagnosis of HCC rupture. HCC was diagnosed based on the diagnostic criteria issued by the American Association for the Study of Liver Diseases ([@b17-ol-0-0-11037]). HCC was staged according to the Barcelona Clinic Liver Cancer (BCLC) staging system ([@b18-ol-0-0-11037]). Spontaneous HCC rupture was diagnosed as disruption of the peritumoral liver capsule with surrounding fluid in the perihepatic region. Detection was performed by dynamic computed tomography (CT) and the diagnosis included the presence of bloody fluid following abdominal puncture.

Database information, such as age, sex and hypertension history, were reviewed. The presence of shock at diagnosis was reviewed and the results of laboratory examinations, including anemia level, baseline liver functions, viral hepatitis findings and α-fetoprotein (AFP), were evaluated. Details of HCC tumor status, such as tumor number, tumor size, the presence of vascular thrombosis and the presence of extra-hepatic invasion, were obtained by contrast-enhanced CT or magnetic resonance imaging (MRI) scans. The present study was approved by the Clinical Research Ethics Committee of Fudan University Affiliated Zhongshan Hospital.

### Treatment procedure

Following stabilization of the hemodynamic status by volume replacement and transfusion, the patients underwent a full clinical assessment to evaluate their suitability for surgical treatment. Contraindications for surgical therapy were determined as follows: Presence of poorly controlled predominant ascites and/or hepatic encephalopathy, a prolonged prothrombin time \>4 sec and poor performance status. In hemodynamically unstable patients with an apparent continuous hemorrhage, TACE was considered if reserve liver function was relatively good regardless of the correction for coagulopathy.

TACE or open surgery was immediately performed following diagnosis. These methods were performed concomitantly with supportive treatment. TACE was performed by femoral artery puncture using the Seldinger method ([@b19-ol-0-0-11037]). A total of 39 patients were enrolled. Prior to TACE, thorough angiography was performed to identify all feeding arteries of the tumor. Digital subtraction angiography was performed to observe tumor staining and to confirm the arterial feeders of the tumor. Following the introduction of a catheter using the Seldinger technique through the femoral artery, a mixture of 5--20 ml lipiodol, epirubicin suspension and gelatin sponge fragments or granules was injected into the tumor-feeding arteries based on the tumor size and the degree of hemorrhage. According to the liver function status, 100--150 mg oxaliplatin or 5-fluorouracil was slowly perfused into the feeding artery under the guidance of digital subtraction angiography by a catheter. For patients with a Child-Pugh score ([@b20-ol-0-0-11037],[@b21-ol-0-0-11037]) of 5 and a white blood cell count ≥3×10^9^/l, 150 mg oxaliplatin was given, while patients with a Child-Pugh score ≥6 or a white blood cell count \<3×10^9^/l, 100 mg oxaliplatin was given. All patients received 1 g 5-fluorouracil. Angiography was performed to determine the extent of embolization. A total of 31 patients with ruptured HCC underwent hepatic resection. Hepatic portal interdiction was used in 18 patients and 13 patients received blood transfusion during the procedure.

### Follow-up of patients with ruptured HCC following treatment

The median follow-up period was 20 months. During follow-up, the laboratory tests were obtained on the 7th day following the operation. Contrast-enhanced liver CT or MRI scans were performed at 1 month following the operation and subsequently once every 3 months. The main endpoint of the study was the control rate of rupture and hemorrhage of HCC. The overall survival (OS) and the safety of the procedure were used as secondary endpoints.

### Statistical analysis

Categorical variables are expressed as frequencies and percentages and were analyzed with the chi-square test. Continuous variables are expressed as medians and ranges and were analyzed with the independent sample t-test. Factors that were found to be significant in univariate analysis were subjected to multivariate analysis. Cox regression hazard model was used to identify independent prognostic factors associated with OS. Propensity score matching (PSM) analysis was used to avoid bias between the TACE and surgery groups. The OS rates were analyzed using the Kaplan-Meier method, and the differences were analyzed with the log-rank test. Statistical analyses were performed using SPSS 21 (IBM Corp.). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baseline characteristics of patients

A total of 70 patients were enrolled in the present study between April 2015 and October 2017. A total of 39 patients were treated with TACE following spontaneous HCC rupture and 31 were treated with open surgery. The median age was 54 years (range, 31--86 years) and the sample size comprised 55 men and 15 women. A total of 52 (74.3%) patients exhibited hepatitis B virus (HBV) infection. Hepatitis C virus (HCV) infection was not detected in any patient in the present study. The AFP levels in 37 (52.9%) patients were \>400 ng/ml. The Child-Pugh classification indicated that 40 (57.1%) patients were included in class A, 22 (31.4%) in class B and eight (11.4%) in class C. BCLC staging at diagnosis indicated that one (1.4%) patient was classified as stage A, 46 (65.7%) patients were classified as stage B, and 23 (32.9%) as stage C. Of the 70 patients, 17 (24.3%) exhibited vascular thrombosis. A total of 40 (57.1%) patients presented with a single tumor, whereas 30 (42.9%) patients had multiple tumors. The maximum tumor size in 17 (24.3%) and 24 (34.3%) patients was \<5 and \>10 cm, respectively ([Table I](#tI-ol-0-0-11037){ref-type="table"}). Eight (20.5%) patients exhibited distant metastasis, whereas three patients presented with metastases in more than one location. Among these, seven metastases were present in the lung, three in the bone and three in distant lymph nodes. These eight patients with distant metastasis were treated with TACE. In the surgery group, no patients exhibited distant metastasis ([Table I](#tI-ol-0-0-11037){ref-type="table"}).

### Safety of TACE and surgical treatment

To evaluate the safety of TACE and resection for patients with HCC exhibiting spontaneous tumor rupture, the post-treatment adverse reactions were investigated. Upper abdominal pain (69.0%), fever (47.1%), neutrophilia (38.6%) and nausea (20%) were the most common adverse reactions. The majority of the toxicity events (54.3% of all reported events) was Grade 2 or less. Grade 3/4 events occurred in 20 patients (14.3%), which included gastrointestinal hemorrhage, cardiac failure, pulmonary embolism, shock and recurrent tumor rupture. All of these patients recovered and were discharged following symptomatic and supportive treatment, with the exception of two cases of severe hemorrhagic shock and hepatic failure prior to TACE treatment. These patients did not survive the hospitalization period. The median duration of hospital admission of patients in the TACE and surgery groups were 7 and 13 days, respectively (P\<0.01; [Table II](#tII-ol-0-0-11037){ref-type="table"}).

In the TACE group, 21 patients reported various degrees of upper abdominal pain. This symptom was considered to be associated with tumor rupture following embolism. Nausea and vomiting occurred in 12 patients following TACE treatment. However, the majority of the patients were generally relieved of symptoms within 24--48 h. Fever with a body temperature between 37.5 and 39.5°C occurred in 15 patients. This symptom gradually decreased within 3--7 days, possibly due to tumor necrosis and absorption. The majority of the patients exhibited transient liver damage following TACE and recovered to normal or baseline levels within 5--8 days following liver protection therapy. A total of two patients exhibited renal failure, of which only one was newly diagnosed following TACE treatment. Furthermore, one patient developed mild pulmonary embolism and another developed acute cholecystitis of The National Cancer Institute Common Terminology Criteria for Adverse Events ([@b22-ol-0-0-11037]) level 2. The cause of this was considered to be ectopic embolism. Following TACE, the patient with cholecystitis recovered within 8 days of antibiotic treatment, intravascular fluid replacement and fasting. A total of six patients presented with shock in the TACE group. However, five of these were in shock prior to the procedure. A total of two patients (5.3%) exhibited re-rupture of HCC within 1 month following TACE and underwent retreatment. No hepatic encephalopathy, gastrointestinal bleeding, liver abscess or other serious complications occurred.

In the surgery group, a high number of patients presented with abdominal pain and a number of patients exhibited nausea and vomiting following treatment (P\<0.05). There were no significant differences in the incidence of any other complications between these two treatment groups. Two patients exhibited massive hydrothorax, both recovering following thoracic puncturing and piping. One patient experienced gastrointestinal hemorrhage and recovered following 7 days of conservative treatment. One patient presented with grade 3 cardiac failure and shock following resection. This patient finally recovered following symptomatic and supportive treatment.

### Univariate and multivariate analysis for predictors of TACE treatment

Prior to multivariate analysis, univariate analysis was conducted in all 39 patients treated with TACE. Univariate analysis resulted in the identification of the following thresholds regarding specific parameters: Maximum tumor size \>10 cm (P=0.044), Child-Pugh score \>7 (P=0.094), serum total bilirubin levels \>1.5 times higher than normal levels (P=0.001) and serum aspartate transferase levels \>3 times higher than normal levels (P=0.086) ([Table III](#tIII-ol-0-0-11037){ref-type="table"}). These thresholds were used as determinants of poor 30-day survival ([Table III](#tIII-ol-0-0-11037){ref-type="table"}). Additional analysis using multivariate Cox regression analysis led to the identification of the following thresholds: Maximum tumor size \>10 cm (HR, 2.739; P=0.034) and serum total bilirubin levels \>30 µmol/l (HR=0.165, P=0.001). These were used as significant determinants of inverse OS ([Table IV](#tIV-ol-0-0-11037){ref-type="table"}; [Fig. 1A and B](#f1-ol-0-0-11037){ref-type="fig"}).

### Comparison of clinical parameters and survival analysis by treatment types

To determine the efficacy and prognosis of TACE for spontaneously ruptured HCC, the OS rates of the patients with ruptured HCC who received TACE and/or surgical treatment was examined. Initially, the clinical parameters of the two therapies were analyzed. No significant difference was noted with regard to the parameters of age distribution and sex ratio between the TACE and surgery groups. The history of hypertension and the characteristics of the tumors, such as maximum tumor size, capsule formation and vascular thrombus, were also similar between the two groups ([Table I](#tI-ol-0-0-11037){ref-type="table"}). The total serum bilirubin levels in the TACE group were significantly higher than those in the surgery group (P\<0.01). Patients in the TACE group exhibited higher Child-Pugh scores and BCLC stages compared with those in patients in the surgery group (P\<0.01; [Fig. 2](#f2-ol-0-0-11037){ref-type="fig"}).

In the TACE group, rupture and hemorrhage of HCC were effectively controlled in 37 (94.9%) patients. All of these patients were discharged, although four underwent second-stage resection. These four patients were excluded when comparing the OS rates between the two treatments. Two (5.1%) patients did not survive during the duration of hospital admission due to severe hemorrhagic shock and consequent hepatic and renal failure. In the surgery group, all patients were effectively treated and discharged. The median survival time periods were 7.4 and 8 months for the TACE and surgery groups, respectively (P\>0.05). The cumulative survival rates at 1, 6 and 12 months were 92.3, 53.8 and 46.2%, and 100, 87.1 and 54.8%, for the TACE and surgery groups, respectively ([Fig. 3](#f3-ol-0-0-11037){ref-type="fig"}). In the TACE group, 17 patients succumbed to hepatic failure, one to brain metastasis and three to massive digestive hemorrhage. The causes of death in the surgery group were similar (12 due to hepatic failure and two due to massive digestive hemorrhage). The cumulative survival rates of the surgery group patients at 1 and 6 months were significantly higher than those noted in the TACE group (P\<0.01). This may be associated with the poor liver function and severe liver cirrhosis noted in the TACE group. However, the mortality rate at the 12-month period did not differ significantly between the two groups (P\>0.05; [Fig. 3A](#f3-ol-0-0-11037){ref-type="fig"}). Survival analysis in 12 pairs of patients from the TACE and surgery groups was matched with PSM. The mortality rate at the 12-month period did not differ significantly between the two groups following PSM (P\>0.05; [Fig. 3B](#f3-ol-0-0-11037){ref-type="fig"}). Additionally, the duration of hospital admission in the TACE group was considerably shorter (P\<0.01; [Fig. 2F](#f2-ol-0-0-11037){ref-type="fig"}). These results demonstrated that TACE and surgery treatment resulted in similar OS rates at the 12-month period, although TACE treatment revealed lower OS rates at the 1- and 6-month periods. This indicated that TACE significantly reduces the duration of hospital admission.

Discussion
==========

Spontaneous rupture of HCC is one of the most common emergencies in the advanced stage of this disease ([@b23-ol-0-0-11037]). Various hypotheses have been formulated to explain the exact mechanism that leads to HCC rupture ([@b24-ol-0-0-11037]--[@b26-ol-0-0-11037]). Central necrosis in the growing tumor, portal hypertension, neoplastic invasion causing a local increase of venous pressure within the tumor and a previous vascular injury are associated with the incidence of hemorrhage within the tumor ([@b25-ol-0-0-11037]). The optimal treatment approach for HCC rupture has not been yet identified ([@b27-ol-0-0-11037]). Surgery is considered one of the best options for the treatment of HCC with acute spontaneous rupture ([@b28-ol-0-0-11037]). However, several studies have reported that only a limited number of patients with ruptured HCC can be managed with surgical hepatic resection ([@b29-ol-0-0-11037]--[@b31-ol-0-0-11037]). Additionally, surgery is technically difficult to perform in cases of a severely cirrhotic liver ([@b5-ol-0-0-11037]), and patients with poor liver function and severely ruptured HCC cannot tolerate hepatic resection ([@b32-ol-0-0-11037]). It has been reported that TACE is effective in achieving immediate hemostasis for ruptured HCC ([@b33-ol-0-0-11037]). However, the safety and survival benefits of TACE compared with those of surgical resection remain unclear.

The present study demonstrated that the levels of liver enzymes were significantly higher in the first 3 days following TACE compared with those noted at baseline. These differences were reduced within 7 days and the levels of liver enzymes returned to normal and/or baseline levels. These results indicated that TACE treatment did not cause severe damage to normal liver tissues. Serious injury to the bile duct is an additional risk of TACE that can lead to cholesteatoma, as reported in previous studies ([@b14-ol-0-0-11037]). In the present study, only one patient (2.6%) presented with this complication and recovered in a few days. Furthermore, no other severe complications, such as hepatic encephalopathy, liver abscess or gastrointestinal bleeding, were noted, which had been reported by previous studies ([@b34-ol-0-0-11037]). In the present study, the procedure was well tolerated by all study subjects. The general post-procedure complications were minor and self-limiting.

Kirikoshi *et al* ([@b35-ol-0-0-11037]) reported that poor liver function only influenced the parameter of short-term mortality rate (21 days), whereas long-term survival (140 days) was not noted in any cases of ruptured HCC. In their study, the size of the tumor (diameter \>7 cm) was the only independent factor influencing long-term survival among patients who underwent successful TACE. However, in the present study, the endpoint of a tumor diameter \>5 or 7 cm had no significant effect on the survival rate, as determined by multivariate analysis. By contrast, the endpoints of maximum tumor diameter \>10 cm and serum total bilirubin levels \>30 µmol/l were determined to be independent predictors of survival rate by multivariate analysis. This discrepancy may be associated with the different review time and the different medical history of the subjects. Additional investigations are required to address this discrepancy.

Currently, there is debate regarding the optimal treatment for spontaneous rupture of HCC ([@b23-ol-0-0-11037]). The 30-day mortality rate of the TACE group was reported to be lower than that of the surgery group in a previous study ([@b36-ol-0-0-11037]). The present study revealed that the cumulative survival rate in the open surgical group at 1 month was significantly higher than that of the TACE group, which is in accordance with previous studies. However, the cumulative survival rates at 12 months were similar between the two treatment groups. The clinical characteristics between the TACE and surgery groups were also analyzed and the data indicated that patients in the TACE group exhibited higher Child-Pugh scores and BCLC stages compared with those in patients of the surgical group. Furthermore, comparison of the duration of hospital admission revealed that TACE was associated with a significant reduction in the duration of hospital admission compared with that in the surgical group. These results indicated that the long-term survival rate of patients treated with TACE was similar to that of patients treated with open surgery and hospital admission was shorter.

In conclusion, the present study demonstrated that the majority of the patients exhibited transient liver damage following TACE and liver function recovered to normal or baseline levels within a few days of treatment. TACE treatment did not cause serious complications. The maximum tumor size and baseline bilirubin levels were identified as major factors associated with disease prognosis. TACE exhibited acceptable tolerability in patients with spontaneously ruptured HCC, and long-term mortality rates were similar to those in the open surgery treatment group. Furthermore, TACE treatment significantly reduced the duration of hospital admission. Therefore, TACE is considered an option for unresectable HCC rupture due to its efficacy and safety. The present study may provide useful information for clinicians and may aid the determination of the most appropriate treatment option for spontaneous tumor rupture.
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![Multivariate analysis of factors related to post-treatment mortality. (A) TBIL \>30 µmol/l (P\<0.01) and (B) maximum tumor size \>10 cm (P\<0.05) were independent factors determining overall survival. TBIL, total bilirubin.](ol-18-06-6423-g00){#f1-ol-0-0-11037}

![Comparison of clinical parameters and complications in the two treatment groups. (A) AFP levels were significantly lower in the surgical group than in the TACE group (P\<0.01). (B) Single tumor rate was significantly higher in the surgical group than in the TACE group (P\<0.05). (C) Reserve hepatic function (Child-Pugh score) was better in the surgical group than in the TACE group (P\<0.01). (D) BCLC stage was higher in the surgical group than in the TACE group (P\<0.01). (E) More patients had severe anemia in the TACE group than in the surgery group (P\<0.05). (F) Duration of hospital admission was shorter in the TACE group than in the surgery group (P\<0.05). TACE, transcatheter arterial chemoembolization; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; Hb, hemoglobin.](ol-18-06-6423-g01){#f2-ol-0-0-11037}

![Overall survival of patients with spontaneously ruptured hepatocellular carcinoma following TACE and surgical treatments. The overall survival rates within 12 months in the TACE and surgery groups (A) before and (B) after PSM. The overall survival rate at 12 months did not differ significantly between the two groups (P\>0.05). TACE, transarterial chemoembolization; PSM, propensity score matching.](ol-18-06-6423-g02){#f3-ol-0-0-11037}

###### 

Clinical characteristics of patients with spontaneously ruptured hepatocellular carcinoma.

  Variable                       TACE cases, n (%)   Surgery cases, n (%)   P-value   Total cases, n (%)
  ------------------------------ ------------------- ---------------------- --------- --------------------
  Age \>60 years                 13 (33.3)           7 (22.6)               0.323     20 (28.6)
  Hypertension history           16 (41.0)           12 (38.7)              0.844     28 (40.0)
  Child-Pugh                                                                \<0.001   
    A                            11 (28.2)           29 (93.5)                        40 (57.1)
    B                            21 (53.8)           1 (3.2)                          22 (31.4)
    C                            7 (18)              1 (3.2)                          8 (11.4)
  AFP \>400 ng/l                 27 (69.2)           10 (32.3)              0.002     37 (52.9)
  ALT \>3 N                      7 (17.9)            0 (0.0)                0.015     7 (9.9)
  AST \>3 N                      17 (43.6)           6 (19.4)               0.032     23 (32.9)
  TBIL \>1.5 N                   11 (28.2)           3 (9.7)                0.104     14 (20.0)
  ALB ≤35 g/l                    17 (43.6)           7 (22.6)               0.066     24 (34.3)
  PT \>16 sec                    4 (10.2)            1 (3.2)                0.505     5 (7.1)
  Hb, g/l                                                                   \<0.001   
    \>90                         13 (33.3)           25 (80.6)                        36 (51.4)
    90-60                        23 (59.0)           6 (19.4)                         29 (41.4)
    \<60                         3 (7.7)             0 (0.0)                          3 (4.3)
  Scr \>1.5 N                    2 (5.1)             0 (0.0)                0.499     2 (2.9)
  Positive HBsAg status          35 (89.7)           17 (54.8)              0.002     52 (74.3)
  Maximum tumor size, cm                                                    0.655     
    ≥5                           9 (23.1)            8 (25.8)                         17 (24.3)
    \>5 and ≤10                  18 (46.2)           11 (35.5)                        29 (41.4)
    \>10                         12 (30.7)           12 (38.7)                        24 (34.3)
  Tumor number                                                              0.037     
    Single                       18 (46.2)           22 (70.9)                        40 (57.1)
    Multiple                     21 (53.8)           9 (29.0)                         30 (42.9)
  Capsule formation                                                         0.208     
    Yes                          18 (46.2)           19 (61.3)                        37 (52.9)
    No                           21 (53.8)           12 (38.7)                        33 (47.1)
  Vascular thrombus                                                         0.391     
    Yes                          11 (28.2)           6 (19.4)                         17 (24.3)
    No                           28 (71.8)           25 (80.6)                        53 (75.7)
  Extrahepatic invasion                                                               
  Yes                            8 (20.5)            0 (0.0)                          8 (11.4)
  No                             31 (79.5)           31 (100)               0.007     62 (88.6)
  Shock                          5 (12.8)            0                      0.062     5 (7.1)
  BCLC stage                                                                0.049     
    A                            0 (0.0)             1 (3.2)                          1 (1.4)
    B                            22 (56.4)           24 (77.4)                        46 (65.7)
    C                            17 (43.6)           6 (19.4)                         23 (32.9)
  Hospital admission \>10 days   9 (23.1)            19 (61.3)              \<0.001   28 (40.0)

TACE, transarterial chemoembolization; AFP, α-fetoprotein; N, normal level; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; PT, prothrombin time; Scr, serum creatinine; HbsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer.

###### 

Complications following TACE or surgical treatment.

                                I--II degree (%)   ≥III degree (%)   Total (%)   Total after PSM (%) (12 pairs)                                                           
  ----------------------------- ------------------ ----------------- ----------- -------------------------------- ----------- ----------- --------- ---------- ---------- -------
  Abdominal pain                15 (38.5)          16 (51.6)         6 (15.4)    12 (38.7)                        21 (53.8)   28 (90.3)   \<0.001   8 (66.7)   9 (75.0)   0.653
  Nausea and vomiting           10 (25.6)          2 (6.5)           2 (6.5)     0                                12 (30.8)   2 (6.5)     0.012     4 (33.3)   1 (8.3)    0.132
  Fever                         14 (35.9)          18 (58.1)         1 (2.6)     0                                15 (38.5)   18 (58.1)   0.103     5 (41.7)   6 (50.0)   0.682
  Neutrophilia                  15 (38.5)          12 (38.7)         0           0                                15 (38.5)   12 (38.7)   0.983     4 (33.3)   3 (25.0)   0.653
  Renal failure                 1 (2.6)            1 (3.2)           0           0                                1 (2.6)     1 (3.2)     0.869     0          0          NS
  Cholecystitis                 1 (2.6)            0                 0           0                                1 (2.6)     0           0.369     1 (8.3)    0          0.307
  Recurrent tumor rupture       NS                 NS                2 (5.1)     1 (3.2)                          2 (5.1)     1(3.2)      0.696     0          0          NS
  Shock                         NS                 NS                1 (2.6)     1 (3.2)                          1 (2.6)     1 (3.2)     0.869     0          0          NS
  Respiratory failure           0                  0                 1 (2.6)     0                                1 (2.6)     0           0.369     0          0          NS
  Pulmonary embolism            NS                 NS                1 (2.6)     0                                1 (2.6)     0           0.369     0          0          NS
  Cardiac failure               0                  0                 0           1 (3.2)                          0           1 (3.2)     0.259     0          0          NS
  Gastrointestinal hemorrhage   0                  0                 0           1 (3.2)                          0           1 (3.2)     0.259     0          1 (8.3)    0.307
  Hydrothorax                   0                  2 (6.5)           0           0                                0           2 (6.5)     0.108     0          1 (8.3)    0.307

TACE, transarterial chemoembolization; PSM, propensity score matching; NS not significant.

###### 

Univariate analysis of factors associated with overall survival.

  Factor                       Cases   P-value
  ---------------------------- ------- ---------
  Hypertension history         16      0.923
  Child-Pugh score \>7         14      0.094
  AFP \>400 ng/l               27      0.698
  ALT \>3 N                    7       0.255
  AST \>3 N                    17      0.086
  TBIL \>1.5 N                 11      0.001
  Maximum tumor size \>10 cm   12      0.044
  Vascular thrombus            11      0.950
  Extrahepatic invasion        8       0.622
  BCLC stage C                 17      0.187

AFP, α-fetoprotein; N, normal level; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; BCLC, Barcelona Clinic Liver Cancer.

###### 

Multivariate analysis of factors associated with overall survival.

  Factor                       HR      95% CI         P-value
  ---------------------------- ------- -------------- ---------
  TBIL \>30 µmol/l             0.165   0.055--0.497   0.001
  Maximum tumor size \>10 cm   2.739   1.079--6.955   0.034
  AST \>3 N                    0.615   0.387--2.176   0.170
  Child-Pugh score \>7         1.665   0.634--5.878   0.197

HR, hazard ratio; CI, confidence interval; TBIL, total bilirubin; AST, aspartate aminotransferase; N, normal level.
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